Biosimilar products developed by Samsung Bioepis generated 1.5 trillion won in sales overseas last year. It increased by more than 10% from the previous year, the largest ever.

According to Samsung Bioepis on the 18th, five biosimilars recorded a total of $1.255.1 billion (about 1.5 trillion won) in overseas markets last year. It achieved maximum sales, up 11% from $1.125.8 billion in 2020.

With Samsung Bioepis' marketing partner Biogen, it is a statistic that collects Organon's performance. Biogen sells three types of biosimilars in Europe: Enbrel, Remicade, and Humira for autoimmune diseases. Organon sells these three products in the rest of the country except Europe and Korea. In the U